4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
B&K Corporation Limited (2396) operates in the Biotechnology industry and is headquartered in Qingdao, China with about 103 employees. Its market capitalization is roughly HK$473 million. In the fiscal year ended 2025-12-31, 2396 reported CNY 0M in revenue and (CNY 209M) in net income.
B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China.
Interactive charts & full statements → Open the 2396 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | CNY 0M | CNY 0M | CNY 0M |
| Gross Profit | CNY 0M | CNY 0M | CNY 0M |
| Operating Income (EBIT) | (CNY 206M) | (CNY 207M) | (CNY 80M) |
| Net Income | (CNY 209M) | (CNY 212M) | (CNY 105M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | CNY 0M | CNY 0M | CNY 0M |
| Gross Profit | CNY 0M | — | CNY 0M |
| Operating Income (EBIT) | (CNY 79M) | (CNY 40M) | (CNY 46M) |
| Net Income | (CNY 74M) | (CNY 48M) | (CNY 48M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | CNY 684M | CNY 191M | CNY 263M |
| Total Liabilities | CNY 60M | CNY 40M | CNY 395M |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2396 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms